Telomir Pharmaceuticals, Inc.
TELO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001971532
No open-market purchases or sales by Telomir Pharmaceuticals, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $3.80M in total; no superinvestor holds it.
Holders of 5% or more of TELO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Telomir Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Dejoria John Paul | 13G/A | 5.17%3.55M shares | −4.27 ppfrom 9.44% | Sep 18, 20253 filings | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Telomir Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:40 PM ET | Dejoria John Paul | 13G/A | 5.17%3.55M shares | −4.27 ppfrom 9.44% | Jun 30, 2026 | SEC |
| Feb 12, 20269:24 PM ET | Dejoria John Paul | 13G/A | 9.44%3.25M shares | +3.94 ppfrom 5.50% | Dec 31, 2025 | SEC |
| Sep 18, 20256:48 PM ET | Dejoria John Paul | 13G | 5.50%1.77M shares | New | Sep 9, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Telomir Pharmaceuticals, Inc. shares.
No Form 144 notices for Telomir Pharmaceuticals, Inc. are on file.